[CAS NO. 442-51-3]  Harmine

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [442-51-3]

Catalog
HY-N0737A
Brand
MCE
CAS
442-51-3

DESCRIPTION [442-51-3]

Overview

MDL-
Molecular Weight212.25
Molecular FormulaC13H12N2O
SMILESCC1=NC=CC2=C1NC3=C2C=CC(OC)=C3

For research use only. We do not sell to patients.


Summary

Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase ( DYRK ) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT 2A serotonin receptor , with an K i of 397 nM [1] .


IC50 & Target

5-HT 2A Receptor

397 nM (Ki)

DYRK1A


In Vitro

Harmine inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC 50 of 190 nM [2] .Harmine negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine treatment. The neuronal survival rate in the Harmine-treated group is significantly increased, compared with the TBI group. Administration of Harmine results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine significantly reduces the expression of caspase 3, compared with the TBI group [4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT04716335 Psychiatric University Hospital, Zurich|University of Basel
Emotions|Mood|Cognitive Function 1, Social|Empathy
December 1, 2020 Early Phase 1
NCT05526430 James Murrough|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Icahn School of Medicine at Mount Sinai
Diabetes Mellitus
September 13, 2022 Phase 1

Appearance

Solid



Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 30 mg/mL ( 141.34 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.7114 mL 23.5571 mL 47.1143 mL
5 mM 0.9423 mL 4.7114 mL 9.4229 mL
10 mM 0.4711 mL 2.3557 mL 4.7114 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (11.78 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (11.78 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

9H-Pyrido[3,4-b]indole, 7-methoxy-1-methyl-
7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole
Banisterine
Harmine
Leucoharmine
1-Methyl-7-methoxy-β-carboline
Telepathine
Yageine
Banisterin
Telepathin
Harmin
Yagein